EA032498B1 - ПРОМОТОР Pr13.5 ДЛЯ УСТОЙЧИВЫХ Т-КЛЕТОЧНЫХ И ГУМОРАЛЬНЫХ ИММУННЫХ РЕАКЦИЙ - Google Patents
ПРОМОТОР Pr13.5 ДЛЯ УСТОЙЧИВЫХ Т-КЛЕТОЧНЫХ И ГУМОРАЛЬНЫХ ИММУННЫХ РЕАКЦИЙ Download PDFInfo
- Publication number
- EA032498B1 EA032498B1 EA201590831A EA201590831A EA032498B1 EA 032498 B1 EA032498 B1 EA 032498B1 EA 201590831 A EA201590831 A EA 201590831A EA 201590831 A EA201590831 A EA 201590831A EA 032498 B1 EA032498 B1 EA 032498B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- promoter
- mua
- recombinant
- nucleotide sequence
- cell
- Prior art date
Links
- 230000005867 T cell response Effects 0.000 claims abstract description 20
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract 9
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 9
- 230000006698 induction Effects 0.000 claims abstract 2
- 241000282412 Homo Species 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 abstract description 21
- 238000002649 immunization Methods 0.000 abstract description 20
- 239000000427 antigen Substances 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 18
- 108091007433 antigens Proteins 0.000 abstract description 18
- 241000124008 Mammalia Species 0.000 abstract description 14
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 12
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000007089 vaccinia Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000028996 humoral immune response Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 201000006054 Mulibrey nanism Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590831A1 EA201590831A1 (ru) | 2015-08-31 |
| EA032498B1 true EA032498B1 (ru) | 2019-06-28 |
Family
ID=49513897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590831A EA032498B1 (ru) | 2012-10-28 | 2013-10-28 | ПРОМОТОР Pr13.5 ДЛЯ УСТОЙЧИВЫХ Т-КЛЕТОЧНЫХ И ГУМОРАЛЬНЫХ ИММУННЫХ РЕАКЦИЙ |
| EA201990114A EA201990114A1 (ru) | 2012-10-28 | 2013-10-28 | Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990114A EA201990114A1 (ru) | 2012-10-28 | 2013-10-28 | Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (https=) |
| EP (2) | EP2912183B1 (https=) |
| JP (2) | JP6505016B2 (https=) |
| KR (2) | KR20200087880A (https=) |
| CN (1) | CN104755622B (https=) |
| AU (1) | AU2013337018B2 (https=) |
| BR (1) | BR112015009320A2 (https=) |
| CA (1) | CA2887623C (https=) |
| CY (1) | CY1123181T1 (https=) |
| DK (1) | DK2912183T3 (https=) |
| EA (2) | EA032498B1 (https=) |
| ES (1) | ES2800623T3 (https=) |
| HK (1) | HK1212383A1 (https=) |
| HU (1) | HUE049706T2 (https=) |
| IL (1) | IL238130B (https=) |
| IN (1) | IN2015DN03326A (https=) |
| LT (1) | LT2912183T (https=) |
| MX (2) | MX380483B (https=) |
| MY (2) | MY171687A (https=) |
| NZ (1) | NZ706637A (https=) |
| PT (1) | PT2912183T (https=) |
| SG (2) | SG10201704657WA (https=) |
| SI (1) | SI2912183T1 (https=) |
| UA (1) | UA118340C2 (https=) |
| WO (1) | WO2014063832A1 (https=) |
| ZA (1) | ZA201502892B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2912183B1 (en) * | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| ES2921605T3 (es) | 2016-01-29 | 2022-08-30 | Bavarian Nordic As | Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante |
| JP7053491B2 (ja) * | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| CN110198733B (zh) | 2016-09-28 | 2024-04-30 | 巴法里安诺迪克有限公司 | 用于增强痘病毒中转基因的稳定性的组合物和方法 |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| CN110168092A (zh) | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
| KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
| GB201807932D0 (en) * | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127B (zh) | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| US20230190922A1 (en) | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| EP4164682A1 (en) | 2020-06-10 | 2023-04-19 | Bavarian Nordic A/S | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| JP2024535145A (ja) | 2021-09-03 | 2024-09-27 | バヴァリアン・ノルディック・アクティーゼルスカブ | 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 |
| EP4452306A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| AU2023298083A1 (en) | 2022-06-29 | 2025-01-09 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| US20260049291A1 (en) | 2022-08-18 | 2026-02-19 | Transgene | Chimeric poxviruses |
| EP4648781A1 (en) | 2023-01-12 | 2025-11-19 | Bavarian Nordic A/S | Recombinant modified sarna (vrp) for cancer vaccine |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2025238218A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding antigen-displaying protein nanoparticles |
| WO2025238220A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles |
| WO2025238219A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles |
| WO2025238221A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding multi-antigen-displaying protein nanoparticles |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073431A2 (en) * | 2004-06-25 | 2006-07-13 | Merial Limited | Avipox recombinants expressing foot and mouth disease virus genes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| JP2008301792A (ja) * | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| EP2912183B1 (en) * | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
-
2013
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 MX MX2015005264A patent/MX380483B/es unknown
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en not_active Ceased
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 HK HK16100267.8A patent/HK1212383A1/xx unknown
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Ceased
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active Active
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073431A2 (en) * | 2004-06-25 | 2006-07-13 | Merial Limited | Avipox recombinants expressing foot and mouth disease virus genes |
Non-Patent Citations (10)
| Title |
|---|
| Anonymous: "Vaccinia virus WR, complete genome - Nucleotide - NCBI", GenBank Accession Number AY243312, 14 June 2006 [2006-06-14], XP055095213, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/nuccore/29 692106 [retrieved on 2014-01-08] cited in the application *VACWR018 nucleotide and amino acid sequence* * |
| DAVISON, A.J. ; MOSS, B.: "Structure of vaccinia virus early promoters", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 210, no. 4, 20 December 1989 (1989-12-20), United Kingdom, pages 749 - 769, XP024010295, ISSN: 0022-2836, DOI: 10.1016/0022-2836(89)90107-1 * |
| J A TINE, D E LANAR, D M SMITH, B T WELLDE, P SCHULTHEISS, L A WARE, E B KAUFFMAN, R A WIRTZ, C DE TAISNE, G S HUI, S P CHANG, P C: "NYVAC-Pf7: a poxvirus-vectored, mutliantigen, multistage vaccine candidate for Plasmodium falciparum malaaia.", INFECTION AND IMMUNITY, vol. 64, no. 9, 1 September 1996 (1996-09-01), pages 3833 - 3844, XP055095101 * |
| KAREN BAUR, BRINKMANN, SCHWENEKER, P�TZHOLD, MEISING-HENSCHEL, HERMANN, STEIGERWALD, CHAPLIN, SUTER, HAUSMANN: "Immediate-early expression of a recombinant antigen by modified vaccinia virus Ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses", JOURNAL OF VIROLOGY, vol. 84, no. 17, 1 September 2010 (2010-09-01), pages 8743 - 8752, XP055057695, DOI: 10.1128/JVI.00604-10 * |
| KOTWAL, G.J. ; MOSS, B.: "Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 167, no. 2, 1 December 1988 (1988-12-01), AMSTERDAM, NL, pages 524 - 537, XP023051144, ISSN: 0042-6822 * |
| M WACHSMAN, J H LUO, L AURELIAN, M E PERKUS, E PAOLETTI: "Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity", THE JOURNAL OF GENERAL VIROLOGY, SOC GENERAL MICROBIOL, ENGLAND, 1 September 1989 (1989-09-01), ENGLAND, pages 2513 - 2520, XP055095225, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/2550579> DOI: 10.1099/0022-1317-70-9-2513 * |
| MAGDALINI MOUTAFTSI, DAVID C TSCHARKE, KERRIE VAUGHAN, DAVID M KOELLE, LAWRENCE STERN, MAURICIO CALVO-CALLE, FRANCIS ENNIS, MASANO: "Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens", FUTURE MICROBIOLOGY, vol. 5, no. 2, 1 February 2010 (2010-02-01), pages 221 - 239, XP055095338, ISSN: 17460913, DOI: 10.2217/fmb.09.110 * |
| MAGDALINI, MOUTAFTSI, BUI HUYNH-HOA, PETERS BJOERN, SIDNEY JOHN, SALEK-ARDAKANI SHAHRAM, OSEROFF CARLA, PASQUETTO VALERIE, CROTTY: "Vaccinia Virus-Specific CD4+ T Cell Responses Target a Set of Antigens Largely Distinct from Those Targeted by CD8 T Cell Responses", THE JOURNAL OF IMMUNOLOGY, vol. 178, no. 11, 1 June 2007 (2007-06-01), pages 6814 - 6820, XP055095361 * |
| PERKUS M.E., LIMBACH K., PAOLETTI E.: "CLONING AND EXPRESSION OF FOREIGN GENES IN VACCINIA VIRUS, USING A HOST RANGE SELECTION SYSTEM.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 63., no. 09., 1 September 1989 (1989-09-01), US, pages 3829 - 3836., XP000351647, ISSN: 0022-538X * |
| SONIA T. WENNIER, BRINKMANN KAY, STEINH�U�ER CHARLOTTE, MAYL�NDER NICOLE, MNICH CLAUDIA, WIELERT URSULA, DIRMEIER ULRIKE, HAUSMANN: "A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses", PLOS ONE, vol. 8, no. 8, pages e73511, XP055075403, DOI: 10.1371/journal.pone.0073511 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA032498B1 (ru) | ПРОМОТОР Pr13.5 ДЛЯ УСТОЙЧИВЫХ Т-КЛЕТОЧНЫХ И ГУМОРАЛЬНЫХ ИММУННЫХ РЕАКЦИЙ | |
| Scheid et al. | A method for identification of HIV gp140 binding memory B cells in human blood | |
| EA002390B1 (ru) | Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида | |
| JP2022101658A (ja) | Ｈｉｖワクチン接種および免疫療法 | |
| Schleiss et al. | Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B/pp65 vaccination using a lymphocytic choriomeningitis virus vector | |
| Ratto-Kim et al. | Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens | |
| US10905757B2 (en) | Cross-reactive T cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats | |
| CA3173795A1 (en) | Attenuated poxvirus vector based vaccine for protection against covid-19 | |
| JP7225254B2 (ja) | 非構造タンパク質を含むジカウイルスキメラポリエピトープ、及び免疫原性組成物におけるその使用 | |
| Rodríguez-Martín et al. | Immunization with bovine herpesvirus-4-based vector delivering PPRV-H protein protects sheep from PPRV challenge | |
| EP3792360A1 (en) | Marburg virus vaccine with human replication-deficient adenovirus as vector | |
| CN112220921A (zh) | 一种针对呼吸道合胞病毒感染的组合疫苗 | |
| JP2022177128A (ja) | マルチウイルス特異的ｔ細胞免疫療法 | |
| EP4125944A1 (en) | Infectious disease antigens and vaccines | |
| CN115803049A (zh) | 抗原编码盒 | |
| Wijesundara et al. | IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8+ T cell avidity following HIV-1 recombinant pox viral vaccination | |
| Thomson et al. | Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use | |
| ES2544702T3 (es) | Vacunas en forma de ADNi y métodos para utilizarlas | |
| Isshiki et al. | Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine | |
| Zhang et al. | Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm | |
| Zhang et al. | Comparison of heterologous prime-boost immunization strategies with DNA and recombinant vaccinia virus co-expressing GP3 and GP5 of European type porcine reproductive and respiratory syndrome virus in pigs | |
| US20210052720A1 (en) | Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions | |
| WO2024025906A1 (en) | Hcv antigens and antibodies | |
| Schell et al. | Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody | |
| CN117659164A (zh) | 识别ebv抗原的t细胞受体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG TJ TM |